We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Study of Biventricular Pacing in Heart Patients

By HospiMedica staff writers
Posted on 12 Sep 2000
Print article
A European multi-center trial has validated the therapeutic interest in biventricular pacing as resynchronization therapy in patients with severe heart failure and major intraventricular conduction delay, and shown that it has improved exercise tolerance, symptoms, and quality of life in patients in sinus rhythm treated with atrio-biventricular pacing. The trial, called the Multi-Site Stimulation in Cardiomyopathy (MUSTIC), was conducted under the auspices of the European Society of Cardiology.

The trial involved two patient groups. The first was composed of patients with congestive heart failure, chronic left ventricular systolic dysfunction, and signs of major ventricular asynchrony. Patients were implanted with a standard dual-chamber pacemaker, with an atrial port connected to the left ventricular lead and the ventricular port to the right ventricular lead. Patients were paced on or off in both ventricles but did not know whether they received biventricular pacing or not.

Biventricular pacing resulted in a slight but significant improvement in exercise tolerance, but the patients' quality of life, hospitalization rates, and mortality were not significantly different between the two pacing modes. Afterward, 87% of the patients said they preferred biventricular pacing. The results of this part of the trial were presented at the 22nd Congress of the European Society of Cardiology in Paris (France).

The second group of patients, who had normal sinus rhythm and no conventional indication for permanent cardiac pacing, were implanted with an atrio-biventricular pacemaker connected to three transvenous leads. The exercise tolerance in this group increased by 23% between the no-pacing and the pacing period. Hospitalization rates were found to be three times lower than in the no-pacing period. Afterward, 86% of the patients chose biventricular pacing as their preferred mode of therapy. The results of this part of the trial were reported earlier, at the 21st Scientific Sessions of the North American Society of Cardiac Pacing and Electrophysiology.
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Video Uretero-Renoscope
Olympus URF-V3/V3R
New
Mobile Cart
MS550

Print article

Channels

Surgical Techniques

view channel
Image: The Trilogy Valve with locator technology is the only TAVI system approved for aortic regurgitation (Photo courtesy of JenaValve)

New Transcatheter Valve Found Safe and Effective for Treating Aortic Regurgitation

Aortic regurgitation is a condition in which the aortic valve does not close properly, allowing blood to flow backward into the left ventricle. This results in decreased blood flow from the heart to the... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.